Sfoglia per Autore  

Opzioni
Mostrati risultati da 1 a 16 di 16
Titolo Data di pubblicazione Autore(i) File
Liquid Biopsy as a Tool Exploring in Real-Time Both Genomic Perturbation and Resistance to EGFR Antagonists in Colorectal Cancer 1-gen-2020 Internò, Valeria; Tucci, Marco; Pezzicoli, Gaetano; Silvestris, Franco; Porta, Camillo; Mannavola, Francesco
DLC-1 down-regulation via exosomal miR-106b-3p exchange promotes CRC metastasis by the epithelial-to-mesenchymal transition 1-gen-2020 Mannavola, Francesco; Pezzicoli, Gaetano; Tucci, Marco
Large extracellular vesicles—a new frontier of liquid biopsy in oncology 1-gen-2020 Pezzicoli, G.; Tucci, M.; Lovero, D.; Silvestris, F.; Porta, C.; Mannavola, F.
Abstract 2012: In vitro validation of tumor-derived large extracellular vesicles isolation and characterization as suitable tool for liquid biopsy 1-gen-2021 Pezzicoli, Gaetano; Lovero, Domenica; Tucci, Marco; Porta, Camillo; Mannavola, Francesco
Beyond ras and braf: Her2, a new actionable oncotarget in advanced colorectal cancer 1-gen-2021 Guarini, C.; Grassi, T.; Pezzicoli, G.; Porta, C.
Combination of immunotherapy and other targeted therapies in advanced cutaneous melanoma 1-gen-2021 Marconcini, Riccardo; Pezzicoli, Gaetano; Stucci, LUIGIA STEFANIA; Sergi, MARIA CHIARA; Lospalluti, Lucia; Porta, Camillo Guglielmo Giuseppe; Tucci, MARCO GAETANO
A Glimpse in the Future of Malignant Mesothelioma Treatment 1-gen-2021 Pezzicoli, G.; Rizzo, M.; Perrone, M.; Minei, S.; Mutti, L.; Porta, C.
Uterine carcinosarcoma: An overview 1-gen-2021 Pezzicoli, G.; Moscaritolo, F.; Silvestris, E.; Silvestris, F.; Cormio, G.; Porta, C.; D'Oronzo, S.
Playing the devil’s advocate: Should we give a second chance to mTOR inhibition in renal clear cell carcinoma? – ie strategies to revert resistance to mtor inhibitors 1-gen-2021 Pezzicoli, G.; Filoni, E.; Gernone, A.; Cosmai, L.; Rizzo, M.; Porta, C.
Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives 1-gen-2021 Mandriani, B.; Pelle', E.; Pezzicoli, G.; Strosberg, J.; Abate-Daga, D.; Guarini, A.; Cives, M.; Porta, C.
Biliary tract cancers: moving from the present standards of care towards the use of immune checkpoint inhibitors 1-gen-2021 Pezzicoli, Gaetano; Triggiano, Giacomo; Sergi, Maria Chiara; Mannavola, Francesco; Porta, Camillo; Tucci, Marco
MiT translocation renal cell carcinoma: A review of the literature from molecular characterization to clinical management 1-gen-2022 Rizzo, Mimma; Pezzicoli, Gaetano; Santoni, Matteo; Caliò, Anna; Martignoni, Guido; Porta, Camillo
IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinoma 1-gen-2022 Rizzo, Mimma; Varnier, Luca; Pezzicoli, Gaetano; Pirovano, Marta; Cosmai, Laura; Porta, Camillo
Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications 1-gen-2022 Lauricella, Eleonora; Mandriani, Barbara; Cavallo, Federica; Pezzicoli, Gaetano; Chaoul, Nada; Porta, Camillo; Cives, Mauro
[The Treatment of Metastatic Renal Cell Carcinoma: An Update] 1-gen-2023 Pezzicoli, Gaetano; Ganini, Carlo; Re Sartò, Giulia Vanessa; Pirovano, Marta; Cosmai, Laura; Porta, Camillo
Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification 1-gen-2023 Rizzo, Mimma; Caliò, Anna; Brunelli, Matteo; Pezzicoli, Gaetano; Ganini, Carlo; Martignoni, Guido; Porta, Camillo Guglielmo Giuseppe
Mostrati risultati da 1 a 16 di 16
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile